EUVIMEDEUVIMED entdecken
Crossref

Response to the letter to the editor letter to the editor regarding article: “efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature”

Pietro Orlando, Letizia Flammia, Emanuele Vivarelli, Andrea Matucci, Alessandra Vultaggio, Oreste Gallo, Giandomenico Maggiore

European Archives of Oto-Rhino-Laryngology · 21.11.2026

DOI: 10.1007/s00405-026-10819-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 21.11.2026. Verfasst von Pietro Orlando und 6 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Orlando, P., Flammia, L., Vivarelli, E., Matucci, A., Vultaggio, A., Gallo, O., & Maggiore, G. (2026). Response to the letter to the editor letter to the editor regarding article: “efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature”. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10819-3

Vancouver

Orlando P, Flammia L, Vivarelli E, Matucci A, Vultaggio A, Gallo O, et al. Response to the letter to the editor letter to the editor regarding article: “efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature”. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-026-10819-3

BibTeX
@article{Orlando2026,
  author = {Orlando, Pietro and Flammia, Letizia and Vivarelli, Emanuele and Matucci, Andrea and Vultaggio, Alessandra and Gallo, Oreste and Maggiore, Giandomenico},
  title = {Response to the letter to the editor letter to the editor regarding article: “efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature”},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  doi = {10.1007/s00405-026-10819-3}
}
Kostenlos starten →